Web Trader MT5 
Neuralink is a private company, meaning there’s currently no publicly traded Neuralink stock available for purchase on major exchanges.
Have you ever asked yourself if the next frontier of human evolution, merging the brain with artificial intelligence, is an opportunity you can actually own a piece of today?
The headlines about Elon Musk’s neurotechnology venture are constant, but the reality of how to invest in Neuralink is more complicated than looking for a ticker symbol on a brokerage app. For many people looking at how to buy Neuralink stock, the fact that the company is still privately held can be a roadblock.
This guide covers the company’s private status, the difficulties for retail investors and how to position a portfolio toward the broader neurotechnology space.
Is Neuralink Publicly Traded?
Neuralink is privately held, and its stock isn’t traded on any public exchange.
Neuralink is not a public company, so you won’t find a ticker for Neuralink on the New York Stock Exchange (NYSE) or the Nasdaq. In finance, a private company is owned by its founders, its employees and a small group of venture capital firms.
Unlike public companies, private firms are under no obligation to disclose their financial condition to the public or sell shares to the average investor. Neuralink is playing the high-stakes game of Brain-Computer Interface (BCI).
The field is about creating a direct communication channel between the electrical signals of the brain and external software.
The company has turned to private funding rounds rather than public markets because of the capital-intensive nature of the research and the long-term clinical development. To date, Neuralink has raised hundreds of millions of dollars from private investors to fund its ambitious neurotechnology research.
Neuralink has raised approximately $1.3 billion in total funding across six rounds since its founding, backed by Google Ventures, Sequoia Capital, and Founders Fund.
What Is Neuralink and What Does It Do?
Neuralink is a neurotechnology company developing implantable brain–machine interfaces (“brain-to-chip” interfaces) that allow humans to communicate and control digital devices with their minds.
The company’s core mission is to solve various neurological conditions and, eventually, reach a symbiotic relationship between human intelligence and AI. The main device, called the “Link,” is a small, coin-sized implant placed under the skull. It monitors the activity of thousands of neurons using microscopic threads.
Key Focus Areas of Neuralink
| Feature | Description |
| The Implant | A low-power chip that processes neural signals and transmits them wirelessly. |
| The R1 Robot | A specialized surgical robot designed to insert the delicate threads into the brain. |
| Clinical Trials | Ongoing studies to assist patients with quadriplegia in controlling cursors or keyboards. |
| Regulatory Path | Collaboration with the FDA to ensure the safety and efficacy of the medical device. |
Excellent progress has been shown in recent milestones. The FDA gave “Breakthrough Device” status to Neuralink’s “Blindsight” implant, which aims to restore sight. It’s strictly about medical and research results, not about making it immediately available to the public for commercial purposes.
Can You Buy Neuralink Stock?
Retail investors usually can’t buy Neuralink shares directly because the company has not yet held an initial public offering.
In the present financial environment, ownership is limited to “accredited investors” individuals or entities who meet high income or net worth standards. These requirements exist because investing in a private company is far more risky, less liquid and less transparent than buying shares in a public corporation.
You can’t buy shares on a regular exchange, but there are “secondary markets” where employees or early investors sell their private shares. However, these platforms usually have high entry barriers and minimum investment amounts. Until there is a public listing, these shares will be unavailable to the average person.
How Can You Get Indirect Exposure to Neuralink?
Direct ownership is limited but investors can get exposure to the neurotechnology space by investing in publicly traded medical technology companies and sector funds.
You can’t invest directly in Neuralink, so the next best thing is to look at the ecosystem around it. The BCI and neurotech industries are growing, and several public companies are developing similar or complementary technology.
Publicly Listed Neurotechnology Companies
The neurotechnology space consists of both large established medical device companies as well as smaller niche players. These companies are often focused on:
- Deep brain stimulation (DBS) devices.
- Spinal cord stimulation.
- Neuroimaging and diagnostic software.
Investors can find companies already trading on public exchanges by researching the broader category of biotech stocks. These companies are heavily regulated and are available through most standard brokerage accounts.
Healthcare and MedTech ETFs
Exchange-Traded Funds (ETFs) are a way to play the entire medical innovation space. An ETF doesn’t pick a single company; it invests in a basket of stocks linked to healthcare tech, robotics and biotech. This reduces the risk of failure or regulatory setback of any single company’s clinical trial.
Will Neuralink Have an IPO?
Neuralink has not yet made any official announcements about an initial public offering (IPO).
An initial public offering (IPO) is when a private company sells shares on a stock exchange to become a public company. Historically, Elon Musk has kept his companies private for a long time (like SpaceX) so that he could focus on the long haul without the distraction of quarterly earnings.
If Neuralink ever decided to go public, it would have to file documents with the Securities and Exchange Commission (SEC). Investors can watch for the following for potential news:
- S-1 Filings: The formal registration form that the SEC requires before an IPO.
- Company Press Releases: Official statements on funding or structural changes.
- Regulatory Updates: Significant FDA approvals indicating commercial potential.
What Should You Know Before Considering Neuralink Exposure?
Investing in neurotech is highly speculative and comes with unique risks not found in traditional stock market investments.
Before trying to find ways to get exposure to the sector, it’s important to understand the landscape. But a report from the International Brain Initiative forecasts significant growth for the BCI market, even with technical and ethical hurdles still in place.
The global BCI market is projected to grow from $2.8 billion to $9.17 billion, at a CAGR of 16% over the coming years.
- Private Company Risk: The shares of private companies have limited liquidity. If you do manage to buy them, you may find it difficult to sell them, either easily or for their fair price.
- Long Development Cycles: The development of a medical device from the prototype stage to an approved commercial product can take over 10 years.
- Regulatory Review: The FDA employs a rigorous multi-step approval process. One failed clinical trial can cost a company years.
- Speculative Nature: A lot of the value in companies like Neuralink is derived from “future potential” rather than current revenue.
- Portfolio Allocation: High-risk sectors (e.g., Neurotech) should be a small part of a well-diversified portfolio
FAQs
No, Neuralink is a private company and does not have a stock ticker symbol that is available to the public.
It is owned by its co-founder Elon Musk, its employees and private venture capital firms such as Founders Fund and Vy Capital.
A BCI is a technology that creates a direct communication pathway between the human brain and an external computer or robotic device.
No, generally. Pre-IPO shares are usually available only to institutional investors or accredited investors via private secondary markets.
Conclusion
Neuralink, one of the world’s most watched private companies, remains off-limits to the average retail investor. Understanding how to invest in Neuralink today is understanding the limitations of the private market.
The potential of brain-computer interfaces is exciting, but for now, the way to get in on them is through indirect plays such as public competitors or diversified healthcare ETFs. As the technology matures and clinical trials continue, the possibility of a future public listing continues to be of great interest to the global investment community.
If you’re looking to explore the world of publicly traded tech and biotech, consider staying up to date on market trends with a STARTRADER educational resource or practicing your strategy with a demo account.
Disclaimer: This content is for educational purposes only and does not constitute investment, financial, or legal advice. CFDs are complex instruments and carry a high risk of rapid money loss due to leverage. Emerging market investments involve additional risks including currency fluctuations, limited liquidity, and regulatory changes. Any references to regulations or market structures are general in nature and subject to change. Seek independent professional advice before making any investment decisions.
Tags
Open Live Account
Please enter a valid country
No results found
No results found
Please enter a valid email
Please enter a valid verification code
1. 8-16 characters + numbers (0-9) 2. blend of letters (A-Z, a-z) 3. special characters (e.g, !a#S%^&)
Please enter the correct format
Please tick the checkbox to proceed
Please tick the checkbox to proceed
Important Notice
STARTRADER does not accept any applications from Australian residents.
To comply with regulatory requirements, clicking the button will redirect you to the STARTRADER website operated by STARTRADER PRIME GLOBAL PTY LTD (ABN 65 156 005 668), an authorized Australian Financial Services Licence holder (AFSL no. 421210) regulated by the Australian Securities and Investments Commission.
CONTINUEImportant Notice for Residents of the United Arab Emirates
In alignment with local regulatory requirements, individuals residing in the United Arab Emirates are requested to proceed via our dedicated regional platform at startrader.ae, which is operated by STARTRADER Global Financial Consultation & Financial Analysis L.L.C.. This entity is licensed by the UAE Capital Market Authority (CMA) under License No. 20200000241, and is authorised to introduce financial services and promote financial products in the UAE.
Please click the "Continue" button below to be redirected.
CONTINUEError! Please try again.
